Charles E Massie
Overview
Explore the profile of Charles E Massie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1990
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pope B, Park G, Lau E, Belic J, Lach R, George A, et al.
Eur Urol
. 2024 Feb;
85(4):407-410.
PMID: 38378299
No abstract available.
2.
Rossi S, Newsham I, Pita S, Brennan K, Park G, Smith C, et al.
Sci Adv
. 2022 Sep;
8(39):eabn9828.
PMID: 36170366
Current gold standard diagnostic strategies are unable to accurately differentiate malignant from benign small renal masses preoperatively; consequently, 20% of patients undergo unnecessary surgery. Devising a more confident presurgical diagnosis...
3.
Smith C, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger A, et al.
Genome Med
. 2020 Mar;
12(1):23.
PMID: 32111235
Background: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods: Here, a combination of untargeted and targeted...
4.
Mouliere F, Chandrananda D, Piskorz A, Moore E, Morris J, Ahlborn L, et al.
Sci Transl Med
. 2018 Nov;
10(466).
PMID: 30404863
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties of plasma cell-free DNA (cfDNA). We hypothesized that...
5.
Mair R, Mouliere F, Smith C, Chandrananda D, Gale D, Marass F, et al.
Cancer Res
. 2018 Nov;
79(1):220-230.
PMID: 30389699
The factors responsible for the low detection rate of cell-free tumor DNA (ctDNA) in the plasma of patients with glioblastoma (GBM) are currently unknown. In this study, we measured circulating...
6.
Asim M, Tarish F, Zecchini H, Sanjiv K, Gelali E, Massie C, et al.
Nat Commun
. 2017 Aug;
8(1):374.
PMID: 28851861
Emerging data demonstrate homologous recombination (HR) defects in castration-resistant prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we demonstrate a direct requirement for the androgen receptor (AR) to...
7.
Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, et al.
Oncotarget
. 2016 Oct;
7(46):74734-74746.
PMID: 27732966
Two independent regions within HNF1B are consistently identified in prostate and ovarian cancer genome-wide association studies (GWAS); their functional roles are unclear. We link prostate cancer (PC) risk SNPs rs11649743...
8.
Methods to Identify Chromatin-Bound Protein Complexes: From Genome-Wide to Locus-Specific Approaches
Massie C
Methods Mol Biol
. 2016 Jun;
1443:139-50.
PMID: 27246338
High-throughput sequencing approaches coupled with functional genomics experiments have facilitated a rapid growth in our understanding of chromatin biology, from genome-wide maps of transcription factor binding and histone modifications to...
9.
Massie C, Mills I, Lynch A
J Steroid Biochem Mol Biol
. 2016 Apr;
166:1-15.
PMID: 27117390
After briefly reviewing the nature of DNA methylation, its general role in cancer and the tools available to interrogate it, we consider the literature surrounding DNA methylation as relating to...
10.
Asim M, Massie C, Orafidiya F, Pertega-Gomes N, Warren A, Esmaeili M, et al.
J Natl Cancer Inst
. 2015 Dec;
108(5).
PMID: 26657335
Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated kinome to identify clinically relevant and druggable effectors of AR signaling. Methods:...